
    
      The study will also evaluate the impact of the pneumococcal vaccine GSK2189242A on
      nasopharyngeal carriage in a subgroup of children called Carriage subgroup. Immunogenicity
      and reactogenicity of the pneumococcal vaccine GSK2189242A will be evaluated in another
      subgroup of children called Immuno/reacto subgroup.

      Protocol Posting has been updated following Protocol Amendment 3, April 2012, leading to the
      addition of a secondary outcome measure.

      Protocol Posting has been updated following Protocol Amendment 7, March 2017, to add
      serological testing for antibodies against the Hib polysaccharide PRP on samples collected 12
      months following booster dose (Month 22) in the Immuno/reacto sub-cohort, in order to
      evaluate the long term persistence of immune responses to co-administered PedvaxHIB vaccine.
    
  